Dual inhibition of FGFR and PI3K/AKT pathways may be a meaningful treatment strategy for other types of cancer that harbor both FGFR3-TACC3 fusion and genomic alteration of the PI3K/AKT pathway. The gene discussed is TACC3; the disease is cancer.